http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
-
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
-
Bausch Health to acquire DURECT for $63 million upfront
-
Bausch Health to acquire DURECT for $63 million upfront
-
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
-
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
-
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopa
-
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
-
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
-
Bausch Health Co. (BHC) Statement on Selection of XIFAXAN for Inflation Reduction Act's Medicare Negotiation Program
-
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
-
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
-
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Compl
-
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
-
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
-
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
-
Bausch Health Announces Second Quarter 2024 Results
-
Bausch Health (BHC) halted, news pending, company is rumored to be negotiating chapter 11 bankruptcy filing
-
Bausch Health (BHC) Files Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
-
Bausch Health (BHC) Announces Updates Related to Norwich XIFAXAN Matters
-
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
-
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
-
Bausch Health Announces First Quarter 2024 Results
-
Bausch Health to Announce First-Quarter 2024 Results on May 2
-
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
-
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
-
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
-
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
-
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversation
-
Bausch Health (BHC) Announces a Phase 2 Investigator-Initiated Study of RELISTOR
-
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
-
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
-
Bausch Health Companies to Present at Cowen Annual Health Care Conference
-
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
-
Salix Announces 2024 Gastrointestinal Health Scholars Program
-
Bausch Health (BHC) Announces Board Changes
-
Bausch Health Announces Board Refreshment
-
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
